Physician profile
Danielle Tom
NPI 1225782816
$1,485.74
in general payments reported to CMS, 2019-2025
15 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $249 · 2023: $354 · 2024: $564 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $215.59 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $199.71 | 2022-2025 | Trelegy Ellipta |
| Abbvie INC. | $177.07 | 2022-2025 | |
| Lilly USA, LLC | $148.44 | 2022-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $141.28 | 2022-2024 | |
| Exact Sciences Corporation | $133.83 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $129.17 | 2022-2023 | Verquvo, Belsomra, Steglujan |
| Astrazeneca Pharmaceuticals Lp | $91.39 | 2023-2025 | Farxiga, Breztri |
| Amgen INC. | $86.40 | 2023-2025 | Otezla, Repatha, Otezla |
| Axsome Therapeutics, INC. | $68.93 | 2024-2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.15 | 2023 | Xifaxan |
| Almatica Pharma LLC | $18.33 | 2024 | Loreev Xr |
| Sumitomo Pharma America, INC. | $17.98 | 2025 | Gemtesa |
| Tris Pharma INC | $14.65 | 2024 | Dyanavel Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Tom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.